These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11521253)

  • 21. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 22. When does compounding become manufacturing?
    Gushee J
    J Am Vet Med Assoc; 1994 Jul; 205(2):235-6. PubMed ID: 7928585
    [No Abstract]   [Full Text] [Related]  

  • 23. Wyeth preemption case ruling sparks labeling confusion.
    Allison M
    Nat Biotechnol; 2009 May; 27(5):399-400. PubMed ID: 19430423
    [No Abstract]   [Full Text] [Related]  

  • 24. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J
    Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454
    [No Abstract]   [Full Text] [Related]  

  • 25. Reaction of FDA to a fundamental change in the nature of regulations.
    Kennedy D
    J Parenter Drug Assoc; 1979; 33(1):17-20. PubMed ID: 253023
    [No Abstract]   [Full Text] [Related]  

  • 26. Parenteral manufacturing and legal regulations.
    Tamura LK
    Bull Parenter Drug Assoc; 1968; 22(6):261-6. PubMed ID: 5727161
    [No Abstract]   [Full Text] [Related]  

  • 27. Current good manufacturing practice: proposed revision of certain requirements for finished pharmaceuticals; proposed rule, May 3, 1996 (61 FR 20103), [Docket No. 95N-0362]. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1996; 50(6):346-51. PubMed ID: 9038078
    [No Abstract]   [Full Text] [Related]  

  • 28. US Congress to consider limits on DTCA.
    Guthrie P
    CMAJ; 2007 May; 176(10):1404. PubMed ID: 17485685
    [No Abstract]   [Full Text] [Related]  

  • 29. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 30. Toward more effective drug regulation.
    Schmidt AM
    FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532
    [No Abstract]   [Full Text] [Related]  

  • 31. Recent developments help the defense of drug companies in 10b-5 cases.
    Salpeter AN; Hutchins H
    Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711
    [No Abstract]   [Full Text] [Related]  

  • 32. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 33. US aims to tighten rules on direct-to-consumer drug ads.
    Vastag B
    Nat Biotechnol; 2007 Mar; 25(3):267. PubMed ID: 17344868
    [No Abstract]   [Full Text] [Related]  

  • 34. Regulatory requirements with regard to the use of investigational new drugs.
    Hodges RM
    Antimicrob Agents Chemother (Bethesda); 1967; 7():16-8. PubMed ID: 5631922
    [No Abstract]   [Full Text] [Related]  

  • 35. Navigating the Hatch-Waxman Act's safe harbor.
    Jones PB
    Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
    [No Abstract]   [Full Text] [Related]  

  • 36. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 37. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA takes action against firms in scandal over generic products.
    Pollner F
    Med World News; 1989 Sep; 30(17):14-5. PubMed ID: 10294736
    [No Abstract]   [Full Text] [Related]  

  • 39. The complexity of compliance in IVD manufacturing.
    Lokas K
    Med Device Technol; 2005 Dec; 16(10):26-7. PubMed ID: 16419923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Foreign establishment registration and listing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Nov; 66(228):59138-61. PubMed ID: 11776289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.